{
    "body": "Which enzyme is targeted by Evolocumab?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24691094", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25410046", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25052769", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24661068", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24477778", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25079474", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24662398", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25470376", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24694531", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24961142", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24481874", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24373748", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25282520", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24953393", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24953396", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25002170", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24859266", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24678979", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25282519", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24255061", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24509273", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24284914", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24598985", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24825642"
    ], 
    "ideal_answer": [
        "Evolocumab (AMG145) is a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) that demonstrated marked reductions in plasma low-density lipoprotein cholesterol concentrations in statin-intolerant patients."
    ], 
    "exact_answer": [
        "proprotein convertase subtilisin/kexin type 9"
    ], 
    "type": "factoid", 
    "id": "54e0d1491388e8454a000014", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 162, 
            "text": "Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24661068", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 353, 
            "offsetInEndSection": 582, 
            "text": "AREAS COVERED: Evolocumab (AMG145) is a monoclonal antibody inhibiting the proprotein convertase subtilisin/kexin type 9 that binds to the liver LDL receptor and prevents it from normal recycling by targeting it for degradation. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24661068", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 212, 
            "text": "Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24598985", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 449, 
            "offsetInEndSection": 560, 
            "text": "We report a pooled analysis from four phase 2 studies of evolocumab (AMG 145), a monoclonal antibody to PCSK9. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24598985", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 148, 
            "text": "Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24509273", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 449, 
            "offsetInEndSection": 775, 
            "text": "METHODS: A pooled analysis of data from 1,359 patients in 4 phase II trials assessed the effects of evolocumab, a fully human monoclonal antibody to PCSK9, on Lp(a), the relationship between Lp(a) and lowering of low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B, and the influence of background statin therapy.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24509273", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1490, 
            "offsetInEndSection": 1597, 
            "text": "CONCLUSIONS: Inhibition of PCSK9 with evolocumab resulted in significant dose-related reductions in Lp(a). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24509273", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 467, 
            "offsetInEndSection": 703, 
            "text": "Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9, including evolocumab (previously AMG 145), dramatically lowered LDL-C in phase 2 clinical trials when administered alone or in combination with a statin. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24481874", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 545, 
            "offsetInEndSection": 722, 
            "text": "Evolocumab (AMG 145) is a fully human monoclonal antibody that binds PCSK9, inhibiting its interaction with the LDL receptor to preserve LDL-receptor recycling and reduce LDL-C.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24477778", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 701, 
            "offsetInEndSection": 1082, 
            "text": "Antibody therapeutics in Phase 3 studies are described, with an emphasis on those with study completion dates in 2014, including antibodies targeting interleukin-17a or the interleukin-17a receptor (secukinumab, ixekizumab, brodalumab), proprotein convertase subtilisin/kexin type 9 (alirocumab, evolocumab, bococizumab), and programmed death 1 receptor (lambrolizumab, nivolumab).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24284914", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 227, 
            "text": "BACKGROUND: Evolocumab (AMG 145), a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein cholesterol (LDL-C) in phase 2 studies of 12 weeks' duration. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24255061", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 479, 
            "offsetInEndSection": 876, 
            "text": "These compounds act either by reducing low-density lipoprotein (LDL) production by inhibiting apolipoprotein B synthesis with an antisense oligonucleotide (mipomersen) or by inhibiting microsomal triglyceride transfer protein (lomitapide), or by enhancing LDL catabolism via monoclonal antibody-mediated inhibition of the activity of proprotein convertase subtilisin/kexin 9 (PCSK9) (evolocumab). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25410046", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 150, 
            "text": "Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25282520", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 292, 
            "offsetInEndSection": 433, 
            "text": "Evolocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), reduced LDL cholesterol by 16% in a pilot study. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25282520", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 159, 
            "text": "PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25282519", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 346, 
            "offsetInEndSection": 470, 
            "text": "We investigated the effect of PCSK9 inhibition with evolocumab (AMG 145) on LDL cholesterol in patients with this disorder. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25282519", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 989, 
            "offsetInEndSection": 1099, 
            "text": "Some of the anti-dyslipidemic drugs which work by PCSK9 inhibition include evolocumab, alirocumab and ALN-PCS.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25079474", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 615, 
            "offsetInEndSection": 842, 
            "text": "We highlight the different steps of this adventure and review the published clinical trials especially those with the anti-PCSK9 antibodies evolocumab (AMG 145) and alirocumab (SAR236553/REGN727), which are in phase III trials.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052769", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 744, 
            "offsetInEndSection": 930, 
            "text": "Monoclonal antibodies against PCSK9 represent so far the most advanced approach in clinical development, with alirocumab, evolocumab and bococizumab under advanced clinical development. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25002170", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 301, 
            "offsetInEndSection": 554, 
            "text": "AREAS COVERED: Evolocumab and alirocumab are fully human monoclonal antibodies inhibiting the proprotein convertase subtilisin/kexin type 9 (PCSK9) that binds to hepatic LDL receptor and prevents it from normal recycling by targeting it for degradation.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24961142", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 692, 
            "offsetInEndSection": 939, 
            "text": "Phase II (for evolocumab and alirocumab) and III (for evolocumab) trials show that PCSK9 inhibitors are equally well tolerated, with adverse events mainly limited to mild-to-moderate nasopharyngitis, injection-site pain, arthralgia and back pain. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24961142", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 837, 
            "offsetInEndSection": 1208, 
            "text": "Four classes of newer lipid-lowering drugs offer promising advances in treating FH, namely the apolipoprotein-B synthesis inhibitors (mipomersen), the microsomal transfer protein inhibitors (lomitapide), the cholesterol ester transfer protein inhibitors (anacetrapib, evacetrapib) and the proprotein convertase subtilisin/kexin type 9 inhibitors (evolocumab, alirocumab).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24953396", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 584, 
            "offsetInEndSection": 762, 
            "text": "Monoclonal antibodies that inhibit proprotein convertase subtilisin/ kexin type 9 (PCSK9), which degrades the LDL receptor, like alirocumab and evolocumab, are in phase 3 trials.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24953393", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 282, 
            "offsetInEndSection": 462, 
            "text": "In support of the drug development program for Evolocumab, a fully human IgG\u2082 antibody that targets PCSK9, a quantitative ELISA to measure free PCSK9 in human serum was developed. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24859266", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 147, 
            "text": "IMPORTANCE: In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24825642", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 168, 
            "text": "Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24694531", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 342, 
            "offsetInEndSection": 580, 
            "text": "Evolocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), demonstrated marked reductions in plasma low-density lipoprotein cholesterol (LDL-C) in a phase 2 study in statin-intolerant patients.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24694531", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 124, 
            "text": "Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24691094", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 173, 
            "offsetInEndSection": 342, 
            "text": "BACKGROUND: Evolocumab, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced LDL-C in phase II trials. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24691094", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 206, 
            "text": "BACKGROUND: Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in phase 2 studies. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24678979", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 198, 
            "text": "Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24662398", 
            "endSection": "title"
        }
    ]
}